Cresco Labs (CRLBF) Equity Income (2020 - 2021)
Cresco Labs' (CRLBF) quarterly Equity Income came in at -$1.2 million in Q1 2021, down 730.56% YoY from $189674.0 in Q1 2020, and down 229.02% on a QoQ basis from $927000.0 in Q4 2020.
Cresco Labs (CRLBF) Equity Income (2020 - 2021) Analysis & Trends
Cresco Labs (CRLBF) has 2 years of Equity Income data on file, last reported at -$1.2 million in Q1 2021.
- Quarterly Equity Income fell 730.56% year-over-year to -$1.2 million in Q1 2021, while the trailing twelve-month figure through Dec 2021 was -$1.2 million (down 277.71% YoY) and the FY2021 annual result came in at -$1.2 million, down 201.27% from the prior year.
- Equity Income declined to -$1.2 million in Q1 2021, from $927000.0 in the prior quarter.
- In the past five years, Equity Income ranged from a high of $927000.0 in Q4 2020 to a low of -$1.2 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -500,000.00 |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 3.38 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Cresco Labs | 290.46 Mn | 226.34 Mn | 86.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | -1.20 Mn |
| Dec 31, 2020 | 927,000.00 |
| Sep 30, 2020 | -134,000.00 |
| Jun 30, 2020 | 24,000.00 |
| Mar 31, 2020 | -144,000.00 |